Home / Market News / $KARD

$KARD news and market catalysts

The 12 most recent market catalysts affecting $KARD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

12 catalysts 2 high impact 1 bullish 2 bearish Biotechnology/Pharmaceuticals
Nov 12, 2026 Corporate Catalyst Neutral Impact 92
Kardigan Reports Third Quarter 2026 Financial Results
Kardigan, Inc. announced its third-quarter 2026 financial results, reporting a net loss of $0.64 per share. This figure is significant because it 'outperformed' the FactSet consens…
Nov 6, 2026 Corporate Catalyst Bullish Impact 65
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial
Kardigan, Inc. has completed enrollment for its Phase 2b KATALYST-AV trial, which is evaluating ataciguat for aortic stenosis. This is a significant operational milestone in drug d…
Nov 4, 2026 Corporate Catalyst Neutral Impact 65
HC Wainwright Initiates Coverage on Kardigan With Buy Rating
Investment firm HC Wainwright has initiated research coverage on Kardigan, Inc., a clinical-stage precision therapeutics company focused on cardiovascular disease. The firm assigne…
Oct 29, 2026 Corporate Catalyst Neutral Impact 65
Cantor Fitzgerald Initiates Coverage on Kardigan, Inc. with Overweight Rating
Cantor Fitzgerald initiated research coverage on Kardigan, Inc., a clinical-stage precision therapeutics company, with an 'Overweight' rating and a $50 price target. This is a posi…
Oct 22, 2026 Corporate Catalyst Neutral Impact 65
Baird Initiates Coverage on Kardigan, Inc. with Outperform Rating
Baird has initiated coverage on Kardigan, Inc., a clinical-stage precision therapeutics company, assigning an 'Outperform' rating and a $43 price target. This event is significant …
Oct 16, 2026 Corporate Catalyst Neutral Impact 55
William Blair Initiates Coverage On Kardigan with Outperform Rating
William Blair's initiation of coverage on Kardigan with an Outperform rating is a positive development for the company. Analyst coverage, especially from a reputable firm, can incr…
Oct 12, 2026 Corporate Catalyst Neutral Impact 65
UBS Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $25
UBS analyst Alice Nettleton has initiated coverage on Kardigan (KARD) with a 'Buy' rating and a $25 price target. This event is significant because new analyst coverage, especially…
Aug 25, 2026 Corporate Catalyst Bearish Impact 55
JP Morgan Maintains Overweight on Kardigan, Lowers Price Target to $46
JP Morgan's analyst Anupam Rama has maintained an 'Overweight' rating on Kardigan, suggesting a belief in the company's long-term growth prospects. However, the simultaneous reduct…
Aug 11, 2026 Corporate Catalyst Bearish Impact 95
Kardigan Q2 EPS $(4.61) Misses $(0.71) Estimate
Kardigan's Q2 earnings report revealed a substantial miss on EPS, with actual losses of $(4.61) significantly worse than the $(0.71) analyst estimate. This 549.3% miss is a strong …
Jul 13, 2026 Corporate Catalyst Neutral Impact 55
Leerink Partners Initiates Coverage On Kardigan with Outperform Rating, Announces Price Target of $37
Leerink Partners has initiated coverage on Kardigan, assigning an Outperform rating and a $37 price target. This event is significant as new analyst coverage, especially with a pos…
Jul 13, 2026 Corporate Catalyst Neutral Impact 65
JP Morgan Initiates Coverage On Kardigan with Overweight Rating, Announces Price Target of $51
JP Morgan's initiation of coverage on Kardigan with an Overweight rating and a $51 price target is a notable event for the company. Analyst coverage, especially from a major invest…
Jul 13, 2026 Corporate Catalyst Neutral Impact 65
Jefferies Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $40
Jefferies analyst Dennis Ding initiated coverage on Kardigan (KARD) with a 'Buy' rating and set a price target of $40. This is a positive development for Kardigan as new analyst co…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.